Innovative Diagnostic Tool Minomic's MiCheck Prostate offers a highly sensitive (95%) and specific blood test for prostate cancer detection, providing a compelling value proposition for healthcare providers seeking advanced diagnostic solutions.

Market Expansion Potential With existing distribution in the US through a CLIA-certified lab and in Australia via Sonic Healthcare, Minomic is positioned to expand testing services into additional territories, presenting sales opportunities in new geographic markets.

Healthcare Cost Savings By significantly reducing false positives and unnecessary biopsies, Minomic's test supports cost-efficient healthcare practices, making it attractive to hospital systems and insurance providers focused on reducing patient care expenses.

Strategic Partnerships Recent collaborations with NSW Government and regulatory support highlight opportunities for partnership with public health agencies, paving the way for broader adoption and integration of Minomic's diagnostics into standard care protocols.

Technology and Data Focus Minomic's use of advanced tech stack and ongoing research publications strengthen its market credibility, providing sales teams with a solid platform to target academic, research institutions, and large healthcare networks interested in cutting-edge diagnostics.